Recently licensed and future CFTR modulators may transform treatment and prognosis in CF but a deeper understanding of the underlying causes of inflammation and individual factors associated with different phenotypes is crucial to develop target-directed and individualized treatments for CF and associated immune diseases. The gene discussed is CFTR; the disease is immune system disorder.